Kimura disease responded well to tofacitinib in three cases
Our report provides valuable clinical evidence that tofacitinib is a promising novel therapeutic option for KD, demonstrating its safety and durable efficacy.
Authors
- Yang Wang (ORCID: https://orcid.org/0000-0001-7805-2861)
- Yu Xiao (ORCID: https://orcid.org/0000-0001-5668-7241)
- Mengzhou Cao
Institutions
- Peking University (CN)
- National Medical Products Administration (CN)
- King Center (US)
- National Clinical Research Center for Digestive Diseases (CN)
- National Clinical Research (US)
- Peking University First Hospital (CN)
- Center for Life Sciences (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1080/09546634.2025.2591481
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00